KCT0003249招募中未知
Biomarker-oriented study of Durvalumab (MEDI4736) in combination with Olaparib and paclitaxel in gastric cancer
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Written informed consent and any locally-required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- •2.Age > 19 years at time of study entry
- •3.Histologically proven gastric cancer
- •4.Unresectable or recurrent
- •5.Previous exposure to 1 palliative chemotherapy for their unresectable or recurrent cancer (Relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy containing 5-Fluoropyrimidine monotherapy or 5-fluoropyrimidine and platinum based regimen is considered as first-line therapy)
- •6.Should have measurable lesion based on RECIST V1.1
- •7.Without previous expose to immune-oncology agents including anti-CTLA4, anti-PD1, anti-PDL1, etc
- •8.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 , and body weight >30 kg
- •9.Life expectancy of > 12weeks
- •10.Adequate normal organ and marrow function as defined below:
- •?Haemoglobin = 10.0 g/dL without transfusion within 28 days
- •?No features of MDS/AML
- •?Absolute neutrophil count (ANC) = 1.5 x 109/L (> 1500 per mm3)
- •?Platelet count = 100 x 109/L (>100,000 per mm3)
- •?Serum bilirubin = 1.5 x institutional upper limit of normal (ULN). <<This will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.>>
- •?AST (SGOT)/ALT (SGPT) = 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be = 5x ULN
- •?Serum creatinine CL>51 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance
- •11.Female subjects must either be of non-reproductive potential or must have a negative serum pregnancy test upon study entry.
- •Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
- •12.Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
排除标准
- •1.Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Previous enrollment or randomization in the present study
- •2.Participation in another clinical study with an investigational product during the last 3weeks
- •3.Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
- •4.Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 28 days prior to the first dose of study drug (14 days prior to the first dose of study drug for subjects who have received prior TKIs
- •5.Brain metastases or spinal cord compression unless the patient is stable (asymptomatic; no evidence of new or emerging brain metastases; and stable and off steroids for at least 14 days prior to start of study treatment). Following radiotherapy and/or surgery of the brain metastases subjects must wait 4 weeks following the intervention and before randomisation with imaging to confirm stability.
- •6.Mean QT interval corrected for heart rate (QTc) =470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia’s Correction
- •7.Current or prior use of immunosuppressive medication within 14days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
- •8.Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- •?Subjects with Grade =2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
- •?Subjects with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.
- •9.Any prior Grade =3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
- •10.Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).
- •11.Active or prior documented inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis)
- •12.History of primary immunodeficiency
- •13.History of allogeneic organ transplant
- •14.History of hypersensitivity to durvalumab or any excipient
- •15.History of hypersensitivity to the combination or comparator agent
- •16.Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •17.History of leptomeningea
研究者
相似试验
招募中
不适用
Biomarker-oriented study of Durvalumab(MEDI4736)/Tremelimumab in combination with gemcitabine/cisplatin in chemotherapy –naïve biliary tract cancerKCT0004505Seoul National University Hospital135
已完成
不适用
An exploratory study of durvalumab (MEDI4736) uptake during concurrent chemoradiotherapy in stage III NSCLC patients using 89Zr-labeled durvalumab PETlung carcinoma1003866610029107lung cancerNL-OMON55251Vrije Universiteit Medisch Centrum10
进行中（未招募）
1 期
Does immunotherapy (durvalumab) accumulate in the tumors of patients with lung cancer receiving chemotherapy together with radiotherapy.EUCTR2019-004284-51-NLAmsterdam UMC, VU University Medical Center10
进行中（未招募）
1 期
Treatment of patients with HIV-1 and advanced solid tumors with Durvalumabadvanced solid tumors in HIV-1 infected patientsEUCTR2016-004524-38-ESSpanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón)20
暂停
1 期
A phase Ib study of durvalumab (MEDI4736) tremelimumab combined with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasiohepatocellular carcinomaJPRN-jRCT2031210046Ogasawara Sadahisa15